Eli Lilly Weight-Loss Drug Mounjaro Cardio Advance Is Bad News for Novo Nordisk - Barron's
1. Mounjaro shows cardiovascular benefits for diabetes patients, boosting LLY's future prospects. 2. LLY could update Mounjaro's label to reflect these advantages, competing with Novo Nordisk. 3. Study involved over 13,000 patients, indicating significant reductions in death rates. 4. Mounjaro demonstrates better performance compared to Trulicity in several health metrics. 5. Stock market responses were muted, reflecting broader investor caution in weight-loss drug sector.